Ashwin Sapra
Partner - Corporate
Pharmaceuticals | Healthcare & Life Sciences
Overview
Ashwin Sapra is a Partner in Trilegal’s Corporate practice group and is widely regarded as one of India’s leading pharmaceutical and healthcare lawyers, with over 25 years of experience advising on the most complex regulatory, transactional, and contentious matters in the sector.
He is a trusted advisor to multinational corporations, leading Indian companies, and healthcare institutions on India’s regulatory regime governing drugs, medical devices, diagnostics, nutraceuticals, and related products. His expertise spans the full product lifecycle, including clinical trials, market entry, pricing and price control, promotional practices, and post-market compliance. Ashwin is particularly recognised for his ability to navigate regulatory uncertainty and deliver commercially pragmatic solutions in India’s highly sensitive and evolving pharmaceutical and healthcare sector.
Ashwin has played a central role in structuring and executing high-value M&A, private equity, and capital markets transactions in the pharmaceutical and healthcare space, where regulatory considerations are often determinative. He regularly leads regulatory due diligence and advises on approval frameworks and compliance risk in complex cross-border deals.
A seasoned litigator, Ashwin represents clients in high-stakes disputes involving product liability, regulatory enforcement, pricing actions, product recalls, and government procurement. He appears regularly before courts, tribunals, and sectoral regulators across India.
Known for his strategic, business-oriented approach, Ashwin advises clients on risk mitigation in the context of shifting legislative and policy landscapes, and is frequently engaged on matters involving ethical compliance, anti-bribery frameworks, and industry codes governing healthcare practices.
He is a recognised thought leader and a regular speaker on legal and policy developments in the healthcare and life sciences sector.
Education
- LL.M., Duke University School of Law; LL.B., Symbiosis Law College, Pune; B.Sc. (Hons) Zoology, University of Delhi
Admissions
- Admitted to practice in India; Member, Delhi High Court Bar Association; Honorary Counsel of Trust, Austrian Embassy in India
Select representative Matters
- Advised global pharmaceutical and medical device companies on market entry and regulatory strategy in India, including pricing and commercialization frameworks.
- Advised a global pharmaceutical and medical device company on issues arising out of a global product recall and legality of regulatory action in product liability matters.
- Led regulatory due diligence and structuring for complex cross-border M&A and private equity investments in the healthcare and life sciences sector.
- Represented clients in high-stakes litigation involving drug pricing controls, product recalls, and regulatory enforcement actions.
- Advised on compliance frameworks relating to clinical trials, promotional practices, and interactions with healthcare professionals.
- Counseled leading healthcare providers on operational and regulatory compliance across multi-specialty hospital platforms.
Select representative clients
- Johnson & Johnson
- Roche Diagnostics
- Eli Lilly
- Glenmark Pharmaceuticals
- Intuitive Surgical
- Zydus Life Sciences
- Fortis Hospitals
- Fresenius Medical Care
- Zimmer Biomet
- Baxter
- Vantive
- GSK
Recognition
- Chambers and Partners (Asia-Pacific): Band 2 (2022–2025)
- India Business Law Journal: A-List Lawyer (2024, 2025)
- Legal Era: Leading Lawyer Champion – Pharma & Healthcare (2024, 2025)
- Legal 500: Leading Individual – Life Sciences & Healthcare (2024)
- Asia Law: Distinguished Practitioner (2024)
- IFLR1000: Highly Regarded (2023)
